BioScrip Announces Steps To Enhance Shareholder Value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
BioScrip (BIOS) Posts Q2 GAAP Loss of $3.60/Share; Will Review Strategic Alternatives
August 10, 2015 7:06 AM EDTBioScrip (NASDAQ: BIOS) reported Q2 EPS of ($3.60), which may not compare with the analyst estimate of ($0.08). Revenue for the quarter came in at $262.4 million versus the consensus estimate of $269.38 million.
Consolidated Adjusted EBITDA was a loss of $2.5 million, a $13.5 million decrease compared to Adjusted EBITDA of $11.0 million in the prior year period. The decrease was primarily due to a lower gross margin revenue mix shift as well as the increase of contractual and bad debt expense; and
BioScrip announced a multi-step plan to enhance shareholder value, improve financial flexibility and position... More
